Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2021 08:00 ET | Source: Oncocyte Corporation

Oncocyte Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction Test

DetermaIO is the first and only immunotherapy clinical test that comprehensively assesses the tumor microenvironment In clinical studies to date across multiple tissue types, DetermaIO has...
October 27, 2021 08:00 ET | Source: Oncocyte Corporation

Oncocyte Strengthens Transplant Intellectual Property Portfolio with US Patent Covering Digital PCR Technology for Early Detection of Organ Transplant Rejection

U.S. patent builds upon prior EU patent protection enabling launch of Therasure Transplant Monitor LDT and FDA kits in both the U.S. and Europe Oncocyte’s recently acquired Therasure Transplant...
October 26, 2021 16:05 ET | Source: Oncocyte Corporation

Oncocyte to Report Third Quarter 2021 Financial Results on Tuesday, November 9th

IRVINE, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...
October 07, 2021 08:00 ET | Source: Oncocyte Corporation

Oncocyte Appoints Gisela A. Paulsen as Chief Operating Officer

IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...
September 30, 2021 08:00 ET | Source: Oncocyte Corporation

Oncocyte Publishes Study Demonstrating Predictive Potential for DetermaIO® Test in Triple Negative Breast Cancer

IRVINE, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...
September 20, 2021 11:35 ET | Source: Oncocyte Corporation

Oncocyte Announces Oral Presentation of New Data on Its DetermaIO™ Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting

Randomized clinical trial data from NeoTRIPaPDL1 study establishes DetermaIO as a predictive biomarker of immunotherapy response Trial Investigators found DetermaIO outperformed 80 other immune...
September 20, 2021 08:00 ET | Source: Oncocyte Corporation

Oncocyte Hosting Two-Part Key Opinion Leader Event Series

Part 1: Transplant Rejection Testing – Wednesday, September 22nd @ 1pmET Part 2: DetermaIO™ in Triple-Negative Breast Cancer – Tuesday, September 28th @ 1pmET IRVINE, Calif., Sept. 20, 2021 (GLOBE...
September 16, 2021 08:00 ET | Source: Oncocyte Corporation

Modern Healthcare Recognizes Oncocyte as One of the 2021 Best Places to Work in Healthcare

CHICAGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...
September 13, 2021 08:00 ET | Source: Oncocyte Corporation

Oncocyte to Present New Data on DetermaIO™ from NeoTRIPaPDL1 Trial in Oral Presentation from Late-Breaking Abstract at ESMO 2021

IRVINE, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...
September 07, 2021 16:05 ET | Source: Oncocyte Corporation

Oncocyte to Participate in the 5th Annual Lake Street Capital Markets Best Ideas Growth Conference

IRVINE, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...